Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial | BMC Medicine User montaukwhaler, in the non small cell lung cancer subreddit, 03 Jan 2023